4.6 Article

Modulation of Cell Surface Protein Free Thiols: A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide

期刊

PLOS ONE
卷 4, 期 12, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0008115

关键词

-

资金

  1. NIH/NCI [1 P50-CA130805-01]
  2. Lymphoma Research Foundation

向作者/读者索取更多资源

Background: There has been much interest in targeting intracellular redox pathways as a therapeutic approach for cancer. Given recent data to suggest that the redox status of extracellular protein thiol groups (i.e. exofacial thiols) effects cell behavior, we hypothesized that redox active anti-cancer agents would modulate exofacial protein thiols. Methodology/Principal Findings: To test this hypothesis, we used the sesquiterpene lactone parthenolide, a known anticancer agent. Using flow cytometry, and western blotting to label free thiols with Alexa Fluor 633 C(5) maleimide dye and N-biotinoyl)-N-(iodoacetyl) ethylendiamine (BIAM), respectively, we show that parthenolide decreases the level of free exofacial thiols on Granta mantle lymphoma cells. In addition, we used immuno-precipitation techniques to identify the central redox regulator thioredoxin, as one of the surface protein thiol targets modified by parthenolide. To examine the functional role of parthenolide induced surface protein thiol modification, we pretreated Granta cells with cell impermeable glutathione (GSH), prior to exposure to parthenolide, and showed that GSH pretreatment; (a) inhibited the interaction of parthenolide with exofacial thiols; (b) inhibited parthenolide mediated activation of JNK and inhibition of NF kappa B, two well established mechanisms of parthenolide activity and; (c) blocked the cytotoxic activity of parthenolide. That GSH had no effect on the parthenolide induced generation of intracellular reactive oxygen species supports the fact that GSH had no effect on intracellular redox. Together these data support the likelihood that GSH inhibits the effect of parthenolide on JNK, NF kappa B and cell death through its direct inhibition of parthenolide's modulation of exofacial thiols. Conclusions/Significance: Based on these data, we postulate that one component of parthenolide's anti-lymphoma activity derives from its ability to modify the redox state of critical exofacial thiols. Further, we propose that cancer cell exofacial thiols may be important and novel targets for therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell & Tissue Engineering

AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells

Shanshan Pei, Mohammad Minhajuddin, Biniam Adane, Nabilah Khan, Brett M. Stevens, Stephen C. Mack, Sisi Lai, Jeremy N. Rich, Anagha Inguva, Kevin M. Shannon, Hyunmin Kim, Aik-Choon Tan, Jason R. Myers, John M. Ashton, Tobias Neff, Daniel A. Pollyea, Clayton A. Smith, Craig T. Jordan

CELL STEM CELL (2018)

Article Oncology

Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells

Haobin Ye, Biniam Adane, Nabilah Khan, Erica Alexeev, Nichole Nusbacher, Mohammad Minhajuddin, Brett M. Stevens, Amanda C. Winters, Xi Lin, John M. Ashton, Enkhtsetseg Purev, Lianping Xing, Daniel A. Pollyea, Catherine A. Lozupone, Natalie J. Serkova, Sean P. Colgan, Craig T. Jordan

CANCER CELL (2018)

Article Biochemistry & Molecular Biology

Cellular Compartmentation and the Redox/Nonredox Functions of NAD+

Chaitanya A. Kulkarni, Paul S. Brookes

ANTIOXIDANTS & REDOX SIGNALING (2019)

Review Hematology

Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?

Daniel A. Pollyea, Craig T. Jordan

CURRENT OPINION IN HEMATOLOGY (2019)

Article Cell Biology

The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells

Biniam Adane, Haobin Ye, Nabilah Khan, Shanshan Pei, Mohammad Minhajuddin, Brett M. Stevens, Courtney L. Jones, Angelo D'Alessandro, Julie A. Reisz, Vadym Zaberezhnyy, Maura Gasparetto, Tzu-Chieh Ho, Kathleen K. Kelly, Jason R. Myers, John M. Ashton, Julie Siegenthaler, Tsutomu Kume, Eric L. Campbell, Daniel A. Pollyea, Michael W. Becker, Craig T. Jordan

CELL REPORTS (2019)

Article Developmental Biology

Fndc-1 contributes to paternal mitochondria elimination in C. elegans

Yunki Lim, Karinna Rubio-Pena, Peter J. Sobraske, Paola A. Molina, Paul S. Brookes, Vincent Galy, Keith Nehrke

DEVELOPMENTAL BIOLOGY (2019)

Article Oncology

Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis

Brett Stevens, Amanda Winters, Jonathan A. Gutman, Aaron Fullerton, Gregory Hemenway, Derek Schatz, Nicholas Miltgen, Qi Wei, Taher Abbasi, Shireen Vali, Neeraj K. Singh, Leylah Drusbosky, Christopher R. Cogle, Andrew Hammes, Diana Abbott, Craig T. Jordan, Clayton Smith, Daniel A. Pollyea

LEUKEMIA RESEARCH (2019)

Article Cardiac & Cardiovascular Systems

Cardioprotection by the mitochondrial unfolded protein response requires ATF5

Yves T. Wang, Yunki Lim, Matthew N. McCall, Kai-Ting Huang, Cole M. Haynes, Keith Nehrke, Paul S. Brookes

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)

Editorial Material Physiology

Swapping mitochondria: a key to understanding susceptibility to neonatal chronic lung disease

Andrew M. Dylag, Paul S. Brookes, Michael A. O'Reilly

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2019)

Article Multidisciplinary Sciences

Early life exposures shape the CD4+ T cell transcriptome, influencing proliferation, differentiation, and mitochondrial dynamics later in life

Catherine G. Burke, Jason R. Myers, Lisbeth A. Boule, Christina M. Post, Paul S. Brookes, B. Paige Lawrence

SCIENTIFIC REPORTS (2019)

Article Biophysics

Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60

Daniel A. Pollyea, Amanda Winters, Christine McMahon, Marc Schwartz, Craig T. Jordan, Rachel Rabinovitch, Diana Abbott, Clayton A. Smith, Jonathan A. Gutman

Summary: The combination therapy of venetoclax and azacitidine has shown promising results in treating AML patients over 60 years old, with potential for improved outcomes compared to maintenance therapy. In particular, allogeneic stem cell transplant following ven/aza treatment in newly diagnosed AML patients shows excellent outcomes, suggesting the need for further investigation to refine timing and patient selection for transplant.

BONE MARROW TRANSPLANTATION (2022)

Article Multidisciplinary Sciences

HSF1 is a driver of leukemia stem cell self-renewal in acute myeloid leukemia

Qianze Dong, Yan Xiu, Yang Wang, Christina Hodgson, Nick Borcherding, Craig Jordan, Jane Buchanan, Eric Taylor, Brett Wagner, Mariah Leidinger, Carol Holman, Dennis J. Thiele, Sean O'Brien, Hai-hui Xue, Jinming Zhao, Qingchang Li, Howard Meyerson, Brendan F. Boyce, Chen Zhao

Summary: The transcription factor HSF1 is specifically required for the maintenance of leukemia stem cells in acute myeloid leukemia (AML), and pharmacologically targeting HSF1 may have broad anti-leukemic effects.

NATURE COMMUNICATIONS (2022)

Article Biochemistry & Molecular Biology

Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax

Rachel Culp-Hill, Brett M. Stevens, Courtney L. Jones, Shanshan Pei, Monika Dzieciatkowska, Mohammad Minhajuddin, Craig T. Jordan, Angelo D'Alessandro

Summary: Recent advances in targeting leukemic stem cells (LSCs) with venetoclax and azacitidine (ven + aza) have improved outcomes for de novo acute myeloid leukemia (AML) patients. However, relapsed AML patients often develop resistance to venetoclax and have poor clinical outcomes. This study shows that fatty acid desaturation drives relapsed AML survival and inhibiting it could be a promising therapeutic target for relapsed AML, as demonstrated by decreased AML viability when combining fatty acid desaturation inhibition with ven + aza.

METABOLITES (2023)

Article Oncology

Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy

Zachary J. Walker, Beau M. Idler, Lorraine N. Davis, Brett M. Stevens, Michael J. VanWyngarden, Denis Ohlstrom, Shelby C. Bearrows, Andrew Hammes, Clayton A. Smith, Craig T. Jordan, Tomer M. Mark, Peter A. Forsberg, Daniel W. Sherbenou

Summary: The study found that multiple myeloma cells from patients generally exhibit significantly increased rates of protein translation compared to normal cells, with over 2.5-fold difference, and demonstrated the inhibitory effect of omacetaxine on multiple myeloma cells. Omacetaxine showed synergy with IMiDs in vitro in multiple myeloma cells, while producing a double-hit on the critical IRF4/c-MYC pathway.

CLINICAL CANCER RESEARCH (2021)

Article Medicine, Research & Experimental

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity

Alisa B. Lee-Sherick, Kristen M. Jacobsen, Curtis J. Henry, Madeline G. Huey, Rebecca E. Parker, Lauren S. Page, Amanda A. Hill, Xiaodong Wang, Stephen Frye, H. Shelton Earp, Craig T. Jordan, Deborah DeRyckere, Douglas K. Graham

JCI INSIGHT (2018)

暂无数据